Abstract:Abstract Background Lamotrigine is approved as a maintenance therapy for bipolar I disorder in many countries, including China in 2021. This study evaluated the efficacy and safety of lamotrigine in controlling relapse and/or recurrence of mood episodes in Chinese patients with bipolar I disorder. Methods Patients aged ≥ 18 years with bipolar I disorder who met response criteria (Clinical Global Impression–Severity [CGI-S] score of ≤ 3 for ≥ 4 consecutive weeks) during treatment with lamotrigine in a 6–16 week open-label (OL) phase, and who were maintained for ≥ 1 week on lamotrigine 200 mg/day monotherapy, were randomised (1:1) to continue receiving lamotrigine 200 mg/day or switch to placebo in a 36-week randomised double-blind (RD) phase. The primary efficacy outcome measure was time from entry into the RD phase to intervention for relapse and/or recurrence of a mood episode (TIME). Post hoc analyses assessed the impact of OL baseline mood severity on TIME. Safety assessments were conducted throughout the study. Results Of 420 patients treated in the OL phase, 264 were randomised to receive lamotrigine (n = 131) or placebo (n = 133). Overall, 112 patients had an intervention for relapse and/or recurrence of a mood episode (lamotrigine, n = 50/130 [38.5%]; placebo, n = 62/133 [46.6%]), with no significant difference in TIME between groups (adjusted hazard ratio [95% confidence interval (CI)] 0.93 [0.64, 1.35]; p = 0.701). Post hoc analyses indicated a significant difference in TIME, favouring lamotrigine over placebo, for patients with baseline CGI-S score ≥ 4 (hazard ratio [95% CI] 0.52 [0.30, 0.89]; p = 0.018) and with baseline Hamilton Depression Rating Scale ≥ 18 or Young Mania Rating Scale ≥ 10 (0.44 [hazard ratio [95% CI] 0.25, 0.78]; p = 0.005). Lamotrigine was well tolerated with no new safety signals. Conclusions Lamotrigine was not significantly superior to placebo in preventing relapse and/or recurrence of mood episodes in this study of Chinese patients with bipolar I disorder but post hoc analyses suggested a therapeutic benefit in patients with moderate/severe mood symptoms at baseline. The discrepancy between these findings and the positive findings of the pivotal studies may be attributable to the symptom severity of the bipolar patients recruited, a high dropout rate, and the comparatively short duration of the RD phase rather than race/ethnicity differences. Clinical trial registration ClinicalTrial.gov Identifier NCT01602510; 21st May 2012; https://clinicaltrials.gov/ct2/show/NCT01602510.

An open-labeled, randomized comparative study of lamotrigine and lithium in treatment of bipolar depression

Olanzapine Versus Lithium in the Acute Treatment of Bipolar Mania: A Double-Blind, Randomized, Controlled Trial

A comparative study of treatment of depression:Mirtazapine vs.fluoxepine

Randomized,multicenter,double blind comparative trial of reboxetine in the treatment of depression with or without anxiety

Efficacy and Safety of Quetiapine Extended Release Monotherapy in Bipolar Depression: a Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial

A Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lamotrigine in the Maintenance Treatment of Chinese Adult Patients with Bipolar I Disorder

Efficacy of Quetiapine Monotherapy and Combination Therapy for Patients with Bipolar Depression with Mixed Features: A Randomized Controlled Pilot Study

Effect of lamotrigine on cognitive function and serum inflammatory factors in patients with depression of recurrent bipolar disorder

A Random, Blinded and Controlled Trial for Evaluating the Efficacy and Safety of Olanzapine and Lithium in the Treatment of Bipolar or Mixed Type Mania

Effect of Lamotrigine on Quality of Life in Patients with Newly Diagnosed Epilepsy

Lamotrigine and Lithium Combination for Treatment of Rapid Cycling Bipolar Disorder: Results From Meta-Analysis

Response and Remission Rates in Chinese Patients with Bipolar Mania Treated for 4 Weeks with Either Quetiapine or Lithium: a Randomized and Double-Blind Study.

Efficacy and Safety of Adding Lurasidone to Ongoing Therapy With Lithium or Valproate for the Treatment of an Acute Bipolar Depressive Episode

The efficacy of lamotrigine in bipolar disorder: A systematic review and meta‐analysis

Randomized,double-blind,controlled,multicenter clinical trial of sustained-release divalproex versus lithium carbonate in the treatment of manic episodes of bipolar disorder typeⅠ

Lamotrigine Therapy for Bipolar Depression: Analysis of Self-Reported Patient Data

Efficacy and Safety of Quetiapine in the Treatment of Bipolar Acute Mania: a Randomized, Double-Blind, Lithium-Controlled Multicenter Study

Lithium plus antipsychotics or anticonvulsants for bipolar disorder: Comparing clinical response and metabolic changes

Comparative efficacy of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network Meta-analysis

The Impact of Quetiapine Monotherapy or in Combination with Lithium on the Thyroid Function in Patients with Bipolar Depression: A Retrospective Study

Comparative efficacy, safety, and tolerability of pharmacotherapies for acute mania in adults: a systematic review and network meta-analysis of randomized controlled trials